NRG, EQT And PX, 3 Utilities Stocks Pushing The Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 29 points (0.2%) at 17,603 as of Monday, Nov. 10, 2014, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,659 issues advancing vs. 1,296 declining with 183 unchanged.

The Utilities sector currently sits up 0.3% versus the S&P 500, which is up 0.3%. Top gainers within the sector include Entergy ( ETR), up 1.4%, Xcel Energy ( XEL), up 1.2% and Dominion Resources ( DCUA), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. NRG Energy ( NRG) is one of the companies pushing the Utilities sector lower today. As of noon trading, NRG Energy is down $0.26 (-0.8%) to $33.46 on light volume. Thus far, 1.5 million shares of NRG Energy exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $33.36-$33.92 after having opened the day at $33.74 as compared to the previous trading day's close of $33.72.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NRG Energy, Inc., together with its subsidiaries, operates as a power and energy company. The company is engaged in the ownership and operation of power generation facilities. NRG Energy has a market cap of $11.0 billion and is part of the utilities industry. Shares are up 17.5% year-to-date as of the close of trading on Friday. Currently there are 8 analysts that rate NRG Energy a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates NRG Energy as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full NRG Energy Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, EQT ( EQT) is down $1.92 (-1.9%) to $96.72 on light volume. Thus far, 455,433 shares of EQT exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $96.72-$99.97 after having opened the day at $99.01 as compared to the previous trading day's close of $98.64.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

EQT Corporation, together with its subsidiaries, operates as a natural gas company in the United States. It operates in two segments, EQT Production and EQT Midstream. EQT has a market cap of $15.1 billion and is part of the energy industry. Shares are up 9.9% year-to-date as of the close of trading on Friday. Currently there are 12 analysts that rate EQT a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates EQT as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full EQT Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Praxair ( PX) is down $0.99 (-0.8%) to $125.68 on light volume. Thus far, 396,293 shares of Praxair exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $125.46-$126.72 after having opened the day at $126.69 as compared to the previous trading day's close of $126.67.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Praxair, Inc. produces, sells, and distributes atmospheric, process, and specialty gases, as well as surface coatings in North America, Europe, South America, and Asia. Praxair has a market cap of $36.9 billion and is part of the chemicals industry. Shares are down 2.6% year-to-date as of the close of trading on Friday. Currently there are 8 analysts that rate Praxair a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Praxair as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, notable return on equity, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Praxair Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the utilities sector could consider Utilities Select Sector SPDR ( XLU) while those bearish on the utilities sector could consider ProShares UltraShort Utilities ( SDP).

null

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus